What is the role of leukotriene inhibitors in respiratory therapy?

Leukotriene inhibitors play a crucial role in respiratory therapy primarily by decreasing inflammation in the airways. These medications work by blocking the action of leukotrienes, which are inflammatory mediators that contribute to airway constriction, mucus production, and the overall inflammatory response in conditions such as asthma and allergic rhinitis. By inhibiting leukotriene receptors or the synthesis of leukotrienes, these drugs help to reduce bronchoconstriction, mucus secretion, and edema in the respiratory tract, leading to improved airflow and relief of symptoms associated with respiratory conditions.

In contrast, the other options do not align with the primary function of leukotriene inhibitors, as they do not activate beta-adrenergic receptors, they do not increase mucus production, and they do not enhance airflow obstruction. Instead, their primary action is to promote better airway function by mitigating the inflammatory process.